FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody or its functional fragment, which binds to a split mutant CALR protein, as well as to a composition containing same. Also disclosed is the use of said antibody or fragment thereof in detecting mutant CALR protein, in screening for detecting a therapeutic agent for treating myeloproliferative neoplasm associated with mutant CALR protein, as well as in diagnosing myeloproliferative neoplasm associated with mutant CALR protein.
EFFECT: invention is effective for preventing or treating myeloproliferative neoplasm associated with the mutant CALR protein.
10 cl, 18 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
